cleodette 0,03 mg/3 mg apvalkotās tabletes
actavis group ptc ehf., iceland - ethinylestradiolum, drospirenonum - apvalkotās tabletes - 0,03 mg/3 mg
cleodette 0,02 mg/3 mg 28 apvalkotās tabletes
actavis group ptc ehf., iceland - ethinylestradiolum, drospirenonum - apvalkotās tabletes - 0,02 mg/3 mg
cleodette 0,02 mg/3 mg apvalkotās tabletes
actavis group ptc ehf., iceland - ethinylestradiolum, drospirenonum - apvalkotās tabletes - 0,02 mg/3 mg
bicalutamide accord 150 mg apvalkotās tabletes
accord healthcare b.v., netherlands - bikalutamīds - apvalkotā tablete - 150 mg
abiraterone norameda 500 mg apvalkotās tabletes
norameda uab, lithuania - abirateroni acetas - apvalkotā tablete - 500 mg
abiraterone g.l. pharma 500 mg apvalkotās tabletes
g.l. pharma gmbh, austria - abirateroni acetas - apvalkotā tablete - 500 mg
abiraterone teva 500 mg apvalkotās tabletes
teva b.v., netherlands - abirateroni acetas - apvalkotā tablete - 500 mg
abiraterone stada 250 mg apvalkotās tabletes
stada arzneimittel ag, germany - abirateroni acetas - apvalkotā tablete - 250 mg
abiraterone stada 500 mg apvalkotās tabletes
stada arzneimittel ag, germany - abirateroni acetas - apvalkotā tablete - 500 mg
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatas audzēji - citi hormonu antagonisti un tiem līdzīgas vielas - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.